D
LIVE

Serial Number

97229686

Owner

Diamond Therapeutics Inc.

Attorney

Gary P. Oakeson

Filing Date

Jan 20, 2022

Add to watchlist:

No watchlists yet
View on USPTO

D Trademark

Serial Number: 97229686

D is a trademark filed by Diamond Therapeutics Inc. on January 20, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 39 (Transportation & Storage), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Diamond Therapeutics Inc. (2 trademarks)

36 Toronto Street, Suite 1170
Toronto M5C2C5 , CA

Entity Type: 03

Trademark Details

Filing Date

January 20, 2022

Registration Date

Not Registered

Goods & Services

Downloadable computer applications for monitoring, sensing, stimulating, measuring, and training brain and neural activity; downloadable computer applications for use in therapy of cognitive states; downloadable computer software applications for monitoring, sensing, stimulating, measuring, and training brain and neural activity; downloadable computer software applications for use in therapy of cognitive states; medical systems comprising recorded and downloadable software and/or hardware for monitoring, sensing, stimulating, measuring, and training brain and neural activity; medical systems comprising recorded and downloadable software and/or hardware for use in therapy of cognitive states; downloadable software as a Medical Device (SaMD) for monitoring, sensing, stimulating, measuring, and training brain and neural activity; downloadable software as a Medical Device (SaMD) for use in therapy of cognitive states; downloadable software as a Medical Device (SaMD) for stimulating nerves

Wholesale distributorship featuring pharmaceuticals, drugs, pharmaceutical preparations and products, and health care products used to improve, treat, and prevent diseases, disorders, conditions, and ailments; wholesale distributorship featuring pharmaceuticals, drugs, pharmaceutical preparations and products, and health care products used to treat mental conditions, illnesses and disorders

Pharmaceutical research and development; pharmaceutical drug development; pharmaceutical research and development in the field of mental health treatments; drug discovery services; consultancy pertaining to pharmacology; medical research in the field of mental health conditions, illnesses, and disorders; neuropsychiatric drug discovery services, including pre-clinical and clinical pharmaceutical drug development; pharmaceutical drug development and discovery relating to new chemical entities, neurogenerative drugs, serotonin receptor agonists and antagonist, abuse deterrent drugs, and pharmaceutical preparations for managing a mental, a behavioral, or a neuropsychiatric condition, or its symptoms

Warehousing services, namely, storage, distribution, pick-up and packing for shipment of pharmaceuticals, pharmaceutical drugs, therapeutics, and health care products, namely, central nervous system health care products used to improve, treat, and prevent diseases, disorders, conditions, and ailments

Custom manufacture for others of pharmaceuticals, pharmaceutical drugs, pharmaceutical preparations and products, and health care products, namely, central nervous system health care products used to improve, treat and prevent diseases, disorders, conditions, and ailments; custom manufacture for others of pharmaceuticals, drugs, pharmaceutical preparations and products, and health care products, namely, central nervous system health care products used to treat mental conditions, illnesses and disorders

International Class 005: Pharmaceutical preparations for the treatment of central nervous system conditions, illnesses, and disorders; pharmaceutical products for the treatment of central nervous system conditions, illnesses, and disorders; pharmaceutical preparations for the treatment of mental conditions, illnesses, and disorders; pharmaceutical drugs for the treatment of mental conditions, illnesses, and disorders; psychedelic pharmaceuticals for the treatment of central nervous system conditions, illnesses, and disorders; psychedelic-based medicines for the treatment of central nervous system conditions, illnesses, and disorders; neurogenerative pharmaceutical drugs; serotonin receptor agonists and antagonist pharmaceutical drugs; drug abuse deterrent products in the nature of low-dose pharmaceutical preparations and products, very low-dose pharmaceutical preparations and products, extended release pharmaceutical preparations and products, and tamper resistant pharmaceutical preparations and products; pharmaceutical preparations for managing a mental, a behavioral, or a neuropsychiatric condition, or its symptoms, namely, motivation, attention, accuracy, response speed, perseverance, cognitive engagement, executive function, mood, and/or behavior; pharmaceutical preparations and products for the treatment of mental conditions, illnesses, and disorders

Electroencephalogram (EEG) devices, namely, electroencephalography (EEG) device comprising a sensor for monitoring and measuring brain and neural activity for medical diagnostic purposes; medical devices for monitoring, sensing, measuring, and training brain and neural activity; medical devices for use in therapy of cognitive states, namely, to monitor, sense, or measure cognitive impairment; medical devices for stimulating nerves; medical device used for treating of mental health disorders non-invasively, namely, comprising a sensor for monitoring and measuring brain and neural activity; medical device used for treating of mental health disorders non-invasively, namely, for monitoring, sensing, stimulating, measuring, and training brain and neural activity

Licensing of intellectual property in the field of pharmaceuticals, drugs, pharmaceutical preparations and products, and health care products used to improve, treat, and prevent diseases, disorders, conditions, and ailments; licensing of intellectual property in the field of pharmaceuticals, drugs, pharmaceutical preparations and products, and health care products used to treat mental conditions, illnesses, and disorders

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
May 15, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 14, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 14, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 6, 2026 GNRN
NON-FINAL ACTION E-MAILED
May 6, 2026 GNRT
NON-FINAL ACTION WRITTEN
May 6, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 15, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 15, 2026 CRFA
ASSIGNED TO LIE
Apr 14, 2026 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 9, 2026 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 12, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 12, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 12, 2026 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 28, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 23, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 23, 2025 GNSL
SUSPENSION LETTER WRITTEN
Apr 23, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 14, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 14, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 15, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 15, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 15, 2025 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 17, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 17, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jul 17, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 26, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 26, 2024 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 26, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 4, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Apr 4, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Apr 4, 2024 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 15, 2024 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 14, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 14, 2023 GNSL
SUSPENSION LETTER WRITTEN
Sep 14, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 19, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 18, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 18, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 24, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 24, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 24, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 4, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 3, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 3, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 3, 2022 GNRN
NON-FINAL ACTION E-MAILED
Nov 3, 2022 GNRT
NON-FINAL ACTION WRITTEN
Nov 3, 2022 CNRT
ASSIGNED TO EXAMINER
Oct 29, 2022 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 3, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 2, 2022 NWOS
NEW APPLICATION ENTERED
Jan 24, 2022 NWAP